Cytokinetics Inc (NASDAQ: CYTK) kicked off on Friday, down -3.23% from the previous trading day, before settling in for the closing price of $35.25. Over the past 52 weeks, CYTK has traded in a range of $29.31-$59.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -20.02% over the last five years. While this was happening, its average annual earnings per share was recorded -6.70%. With a float of $117.03 million, this company’s outstanding shares have now reached $119.60 million.
The firm has a total of 498 workers. Let’s measure their productivity. In terms of profitability, gross margin is -1359.51%, operating margin of -2943.3%, and the pretax margin is -3201.47%.
Cytokinetics Inc (CYTK) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 2.20%, while institutional ownership is 116.39%. The most recent insider transaction that took place on Aug 05 ’25, was worth 72,680. In this transaction EVP Research & Development of this company sold 2,000 shares at a rate of $36.34, taking the stock ownership to the 140,610 shares. Before that another transaction happened on Jul 29 ’25, when Company’s President & CEO sold 5,000 for $36.45, making the entire transaction worth $182,250. This insider now owns 388,108 shares in total.
Cytokinetics Inc (CYTK) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.36 earnings per share (EPS), lower than consensus estimate (set at -1.24) by -0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.51 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.12% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Take a look at Cytokinetics Inc’s (CYTK) current performance indicators. Last quarter, stock had a quick ratio of 6.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 47.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.12, a number that is poised to hit -1.56 in the next quarter and is forecasted to reach -5.47 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Analysing the last 5-days average volume posted by the [Cytokinetics Inc, CYTK], we can find that recorded value of 1.41 million was lower than the volume posted last year of 1.75 million. As of the previous 9 days, the stock’s Stochastic %D was 13.59%.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 25.10%, which indicates a significant increase from 9.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.46 in the past 14 days, which was lower than the 1.78 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.81, while its 200-day Moving Average is $42.46. Now, the first resistance to watch is $36.06. This is followed by the second major resistance level at $38.00. The third major resistance level sits at $39.22. If the price goes on to break the first support level at $32.90, it is likely to go to the next support level at $31.68. Now, if the price goes above the second support level, the third support stands at $29.74.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
The company with the Market Capitalisation of 4.08 billion has total of 119,427K Shares Outstanding. Its annual sales at the moment are 18,470 K in contrast with the sum of -589,530 K annual income. Company’s last quarter sales were recorded 1,580 K and last quarter income was -161,380 K.
